Smokers who use medications like nicotine patches or Zyban to quit smoking has the double success rate than who was prescribed Placebos during clinical trials. But the UK-based International Journal of Clinical Practice stated that 80% of the quitters will be back to smoking again in a year.
Varenicline is a new kind of drug that will improve long term quit rates. It is now under evaluation by the US Food and Drug Administration. Varenicline is the first treatment distinctively intended to target the nicotine dependence symptoms.
Varenicline stimulates dopamine, chunks nicotine receptors, reduces nicotine extraction symptoms and desire for smoke. The clinical trials with the new drug has showed that it may give better success rates than earlier medications.